Clinical Reviews in Allergy & Immunology

, Volume 38, Issue 2, pp 276–286

Antifibrosis: To Reverse the Irreversible

Authors

  • Ziv Paz
    • Department of Medicine “B” and the Center for Autoimmune DiseasesSheba Medical Center
    • The Sackler School of MedicineTel Aviv University
    • Department of Medicine “B” and the Center for Autoimmune DiseasesSheba Medical Center
    • The Sackler School of MedicineTel Aviv University
Article

DOI: 10.1007/s12016-009-8157-7

Cite this article as:
Paz, Z. & Shoenfeld, Y. Clinic Rev Allerg Immunol (2010) 38: 276. doi:10.1007/s12016-009-8157-7

Abstract

Fibrosis is a pathological process that includes scar formation and overproduction of extracellular matrix by the connective tissue as a response to tissue damage. The fibrotic process involves multiple organs and results in progressive life-threatening diseases. Today, we know more about the molecular mechanism that leads to fibrosis involving different type of cells, cytokines, chemokines, and tissue enzymes. Fibrosis was considered an irreversible process, at least clinically, and is still usually treated by anti-inflammatory and immunosuppressive agents. No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different drugs with promising results, like: mycophenolate mofetil, interferon, relaxin, and intravenous immunoglobulin. This review will provide a glance to this heavily investigated subject.

Keywords

FibrosisFibroblastProfibrotic cytokinesAntifibrotic therapiesIVIg

Copyright information

© Humana Press Inc. 2009